Saturday - March 07, 2026

Ulcerative Colitis Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Ulcerative Colitis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Type 1 Diabetes Clinical Trial Pipeline Shows Potential with Active Contributions from 85+ Key Companies | DelveInsight

DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading

TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “TCR Therapy Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Systemic Lupus Erythematosus Pipeline Insights 2026” report provides comprehensive insights about 120+ companies and 140+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape. It covers the Systemic Lupus Erythematosus pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading